Human Influenza Virus Infections

Seminars in Respiratory and Critical Care Medicine

Volumn 37, Issue 4, 2016, Pages 487-500

  Peteranderl, Christin ^a   Herold, Susanne ^a   Schmoldt, Carole ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

antiviral therapy; ARDS; influenza virus; lung injury; pandemic; pneumonia; seasonal; vaccination

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

ARTICLE; CLINICAL FEATURE; HOST; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; PANDEMIC INFLUENZA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RISK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; VIRUS IMMUNITY; VIRUS VIRULENCE; DISEASE EXACERBATION; INFLUENZAVIRUS A; PANDEMIC; VIROLOGY;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INFLUENZAVIRUS A; PANDEMICS;

EID: 84982683056     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0036-1584801     Document Type: Article

References (211)

1. Schmolke M., García-Sastre A. Evasion of innate and adaptive immune responses by influenza A virus. Cell Microbiol: 2010; 12 7 873 880
2. Vossen M. T., Westerhout E. M., Söderberg-Nauclér C., Wiertz E. J. Viral immune evasion: a masterpiece of evolution. Immunogenetics: 2002; 54 8 527 542
3. Abdel-Ghafar A. N., Chotpitayasunondh T., Gao Z., et al. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med: 2008; 358 3 261 273
4. Ungchusak K., Auewarakul P., Dowell S. F., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med: 2005; 352 4 333 340
5. Wu Y., Wu Y., Tefsen B., Shi Y., Gao G. F. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol: 2014; 22 4 183 191
6. García-Sastre A. The neuraminidase of bat influenza viruses is not a neuraminidase. Proc Natl Acad Sci U S A: 2012; 109 46 18635 18636
7. Lowen A. C., Mubareka S., Steel J., Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog: 2007; 3 10 1470 1476
8. Bedford T., Riley S., Barr I. G., et al. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature: 2015; 523 7559 217 220
9. Rambaut A., Pybus O. G., Nelson M. I., Viboud C., Taubenberger J. K., Holmes E. C. The genomic and epidemiological dynamics of human influenza A virus. Nature: 2008; 453 7195 615 619
10. World Health Organization Fact Sheet on Influenza; 2014. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed August 18, 2015
11. Ortiz J. R., Neuzil K. M., Rue T. C., et al. Population-based incidence estimates of influenza-associated respiratory failure hospitalizations, 2003 to 2009. Am J Respir Crit Care Med: 2013; 188 6 710 715
12. Molinari N. A., Ortega-Sanchez I. R., Messonnier M. L., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine: 2007; 25 27 5086 5096
13. Cox N. J., Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med: 2000; 51 407 421
14. Simonsen L., Clarke M. J., Schonberger L. B., Arden N. H., Cox N. J., Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis: 1998; 178 1 53 60
15. Taubenberger J. K. The origin and virulence of the 1918 Spanish influenza virus. Proc Am Philos Soc: 2006; 150 1 86 112
16. Miller M. A., Viboud C., Balinska M., Simonsen L. The signature features of influenza pandemics-implications for policy. N Engl J Med: 2009; 360 25 2595 2598
17. Libster R., Coviello S., Cavalieri M. L., et al. Pediatric hospitalizations due to influenza in 2010 in Argentina. N Engl J Med: 2010; 363 25 2472 2473
18. Tanner W. D., Toth D. J., Gundlapalli A. V. The pandemic potential of avian influenza A(H7N9) virus: a review. Epidemiol Infect: 2015; 143 16 3359 3374
19. Pappaioanou M., Gramer M. Lessons from pandemic H1N1 2009 to improve prevention, detection, and response to influenza pandemics from a One Health perspective. ILAR J: 2010; 51 3 268 280
20. Goldstein T., Mena I., Anthony S. J., et al. Pandemic H1N1 influenza isolated from free-ranging Northern Elephant Seals in 2010 off the central California coast. PLoS ONE: 2013; 8 5 e62259
21. Parrish C. R., Murcia P. R., Holmes E. C. Influenza virus reservoirs and intermediate hosts: dogs, horses, and new possibilities for influenza virus exposure of humans. J Virol: 2015; 89 6 2990 2994
22. Uyeki T. M., Cox N. J. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med: 2013; 368 20 1862 1864
23. Simon P. F., McCorrister S., Hu P., et al. Highly pathogenic H5N1 and novel H7N9 influenza A viruses induce more profound proteomic host responses than seasonal and pandemic H1N1 strains. J Proteome Res: 2015; 14 11 4511 4523
24. H5N1 Avian Flu (H5N1 Bird Flu) Available at: http://wwwflugov/about-the-flu/h5n1/indexhtml. Accessed August 21, 2015
25. WHO Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO 2003-2015. Available at: http://www.who.int/influenza/human-animal-interface/EN-GIP-20150904cumulativeNumberH5N1cases.pdf. Accessed August 21, 2015
26. Areechokchai D., Jiraphongsa C., Laosiritaworn Y., Hanshaoworakul W., O'Reilly M.; Centers for Disease Control and Prevention (CDC). Investigation of avian influenza (H5N1) outbreak in humans-Thailand, 2004. MMWR Suppl: 2006; 55 01 3 6
27. Chen Y., Liang W., Yang S., et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet: 2013; 381 9881 1916 1925
28. WHO Who Risk Assessment of Human infections with avian influenza A (H7N9) Virus. Available at: http://www.who.int/influenza/human-animal-interface/influenza-h7n9/RiskAssessment-H7N9-23Feb20115.pdf?ua=1. Accessed August 21, 2015
29. Xiong X., Martin S. R., Haire L. F., et al. Receptor binding by an H7N9 influenza virus from humans. Nature: 2013; 499 7459 496 499
30. Chan M. C., Chan R. W., Chan L. L., et al. Tropism and innate host responses of a novel avian influenza A H7N9 virus: an analysis of ex-vivo and in-vitro cultures of the human respiratory tract. Lancet Respir Med: 2013; 1 7 534 542
31. Ito T., Couceiro J. N., Kelm S., et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol: 1998; 72 9 7367 7373
32. Janke B. H. Influenza A virus infections in swine: pathogenesis and diagnosis. Vet Pathol: 2014; 51 2 410 426
33. Trock S. C., Burke S. A., Cox N. J. Development of framework for assessing influenza virus pandemic risk. Emerg Infect Dis: 2015; 21 8 1372 1378
34. Valleron A. J., Cori A., Valtat S., Meurisse S., Carrat F., Boëlle P. Y. Transmissibility and geographic spread of the 1889 influenza pandemic. Proc Natl Acad Sci U S A: 2010; 107 19 8778 8781
35. Trotter Y. Jr, Dunn F. L., Drachman R. H., Henderson D. A., Pizzi M., Langmuir A. D. Asian influenza in the United States, 1957-1958. Am J Hyg: 1959; 70 1 34 50
36. Xu R., McBride R., Paulson J. C., Basler C. F., Wilson I. A. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol: 2010; 84 4 1715 1721
37. Lindsay M. I. Jr, Herrmann E. C. Jr, Morrow G. W. Jr, Brown A. L. Jr. Hong Kong influenza: clinical, microbiologic, and pathologic features in 127 cases. JAMA: 1970; 214 10 1825 1832
38. Taubenberger J. K., Morens D. M. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis: 2006; 12 1 15 22
39. Sheng Z. M., Chertow D. S., Ambroggio X., et al. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci U S A: 2011; 108 39 16416 16421
40. Perrone L. A., Plowden J. K., García-Sastre A., Katz J. M., Tumpey T. M. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog: 2008; 4 8 e1000115
41. Dawood F. S., Iuliano A. D., Reed C., et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis: 2012; 12 9 687 695
42. Mukherjee S., Vipat V. C., Mishra A. C., Pawar S. D., Chakrabarti A. K. Pandemic (H1N1) 2009 influenza virus induces weaker host immune responses in vitro: a possible mechanism of high transmissibility. Virol J: 2011; 8 140
43. Rust M. J., Lakadamyali M., Zhang F., Zhuang X. Assembly of endocytic machinery around individual influenza viruses during viral entry. Nat Struct Mol Biol: 2004; 11 6 567 573
44. Pinto L. H., Lamb R. A. The M2 proton channels of influenza A and B viruses. J Biol Chem: 2006; 281 14 8997 9000
45. Mair C. M., Ludwig K., Herrmann A., Sieben C. Receptor binding and pH stability - how influenza A virus hemagglutinin affects host-specific virus infection. Biochim Biophys Acta: 2014; 1838 4 1153 1168
46. Zaraket H., Bridges O. A., Russell C. J. The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus replication and pathogenesis in mice. J Virol: 2013; 87 9 4826 4834
47. Resa-Infante P., Thieme R., Ernst T., et al. Importin-α7 is required for enhanced influenza A virus replication in the alveolar epithelium and severe lung damage in mice. J Virol: 2014; 88 14 8166 8179
48. Gabriel G., Klingel K., Otte A., et al. Differential use of importin-α isoforms governs cell tropism and host adaptation of influenza virus. Nat Commun: 2011; 2 156
49. Gabriel G., Herwig A., Klenk H. D. Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range of influenza A virus. PLoS Pathog: 2008; 4 2 e11
50. Massin P., van der Werf S., Naffakh N. Residue 627 of PB2 is a determinant of cold sensitivity in RNA replication of avian influenza viruses. J Virol: 2001; 75 11 5398 5404
51. Rossman J. S., Lamb R. A. Influenza virus assembly and budding. Virology: 2011; 411 2 229 236
52. Wagner R., Matrosovich M., Klenk H. D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol: 2002; 12 3 159 166
53. Baigent S. J., McCauley J. W. Influenza type A in humans, mammals and birds: determinants of virus virulence, host-range and interspecies transmission. BioEssays: 2003; 25 7 657 671
54. Scull M. A., Gillim-Ross L., Santos C., et al. Avian Influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways. PLoS Pathog: 2009; 5 5 e1000424
55. Tscherne D. M., García-Sastre A. Virulence determinants of pandemic influenza viruses. J Clin Invest: 2011; 121 1 6 13
56. Mänz B., Schwemmle M., Brunotte L. Adaptation of avian influenza A virus polymerase in mammals to overcome the host species barrier. J Virol: 2013; 87 13 7200 7209
57. Scholtissek C., Rohde W., Von Hoyningen V., Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology: 1978; 87 1 13 20
58. Taubenberger J. K., Reid A. H., Lourens R. M., Wang R., Jin G., Fanning T. G. Characterization of the 1918 influenza virus polymerase genes. Nature: 2005; 437 7060 889 893
59. Liu Q., Lu L., Sun Z., Chen G. W., Wen Y., Jiang S. Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. Microbes Infect: 2013; 15 6-7 432 439
60. Long J. S., Howard W. A., Núñez A., et al. The effect of the PB2 mutation 627K on highly pathogenic H5N1 avian influenza virus is dependent on the virus lineage. J Virol: 2013; 87 18 9983 9996
61. Salomon R., Franks J., Govorkova E. A., et al. The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med: 2006; 203 3 689 697
62. Mukherjee S., Majumdar S., Vipat V. C., Mishra A. C., Chakrabarti A. K. Non structural protein of avian influenza A (H11N1) virus is a weaker suppressor of immune responses but capable of inducing apoptosis in host cells. Virol J: 2012; 9 149
63. Munier S., Larcher T., Cormier-Aline F., et al. A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens. J Virol: 2010; 84 2 940 952
64. Herold S., Becker C., Ridge K. M., Budinger G. R. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J: 2015; 45 5 1463 1478
65. Solórzano A., Webby R. J., Lager K. M., Janke B. H., García-Sastre A., Richt J. A. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol: 2005; 79 12 7535 7543
66. Wang X., Li M., Zheng H., et al. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol: 2000; 74 24 11566 11573
67. Fouchier R. A., Schneeberger P. M., Rozendaal F. W., et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A: 2004; 101 5 1356 1361
68. Steinhauer D. A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology: 1999; 258 1 1 20
69. Klenk H. D., Garten W. Host cell proteases controlling virus pathogenicity. Trends Microbiol: 1994; 2 2 39 43
70. Tate M. D., Job E. R., Deng Y. M., Gunalan V., Maurer-Stroh S., Reading P. C. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses: 2014; 6 3 1294 1316
71. Kim J. I., Park M. S. N-linked glycosylation in the hemagglutinin of influenza A viruses. Yonsei Med J: 2012; 53 5 886 893
72. Vigerust D. J., Ulett K. B., Boyd K. L., Madsen J., Hawgood S., McCullers J. A. N-linked glycosylation attenuates H3N2 influenza viruses. J Virol: 2007; 81 16 8593 8600
73. Bautista E., Chotpitayasunondh T., Gao Z., et al. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med: 2010; 362 18 1708 1719
74. Short K. R., Kroeze E. J., Fouchier R. A., Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis: 2014; 14 1 57 69
75. Gack M. U., Shin Y. C., Joo C. H., et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature: 2007; 446 7138 916 920
76. Opitz B., Rejaibi A., Dauber B., et al. IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein. Cell Microbiol: 2007; 9 4 930 938
77. Clemens M. J., Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res: 1997; 17 9 503 524
78. Gil J., Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis: 2000; 5 2 107 114
79. Kumar A., Haque J., Lacoste J., Hiscott J., Williams B. R. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci U S A: 1994; 91 14 6288 6292
80. Perona-Wright G., Kohlmeier J. E., Bassity E., et al. Persistent loss of IL-27 responsiveness in CD8+ memory T cells abrogates IL-10 expression in a recall response. Proc Natl Acad Sci U S A: 2012; 109 45 18535 18540
81. Sun J., Dodd H., Moser E. K., Sharma R., Braciale T. J. CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat Immunol: 2011; 12 4 327 334
82. Sun J., Madan R., Karp C. L., Braciale T. J. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med: 2009; 15 3 277 284
83. Ito Y., Torii Y., Ohta R., et al. Increased levels of cytokines and high-mobility group box 1 are associated with the development of severe pneumonia, but not acute encephalopathy, in 2009 H1N1 influenza-infected children. Cytokine: 2011; 56 2 180 187
84. Tsai S. Y., Segovia J. A., Chang T. H., et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway. PLoS Pathog: 2014; 10 1 e1003848
85. Kumagai Y., Takeuchi O., Kato H., et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity: 2007; 27 2 240 252
86. Wang J., Nikrad M. P., Travanty E. A., et al. Innate immune response of human alveolar macrophages during influenza A infection. PLoS ONE: 2012; 7 3 e29879
87. Kim H. M., Lee Y. W., Lee K. J., et al. Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. J Virol: 2008; 82 9 4265 4274
88. Tumpey T. M., García-Sastre A., Taubenberger J. K., et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol: 2005; 79 23 14933 14944
89. Imai Y., Kuba K., Neely G. G., et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell: 2008; 133 2 235 249
90. Tate M. D., Brooks A. G., Reading P. C. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir Res: 2008; 9 57
91. Tate M. D., Deng Y. M., Jones J. E., Anderson G. P., Brooks A. G., Reading P. C. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol: 2009; 183 11 7441 7450
92. Narasaraju T., Yang E., Samy R. P., et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol: 2011; 179 1 199 210
93. Zemans R. L., Colgan S. P., Downey G. P. Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol: 2009; 40 5 519 535
94. Saffarzadeh M., Juenemann C., Queisser M. A., et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS ONE: 2012; 7 2 e32366
95. Amulic B., Cazalet C., Hayes G. L., Metzler K. D., Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol: 2012; 30 459 489
96. Brandes M., Klauschen F., Kuchen S., Germain R. N. A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell: 2013; 154 1 197 212
97. Ichikawa A., Kuba K., Morita M., et al. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am J Respir Crit Care Med: 2013; 187 1 65 77
98. Tavian M., Péault B. Embryonic development of the human hematopoietic system. Int J Dev Biol: 2005; 49 2-3 243 250
99. Fogg D. K., Sibon C., Miled C., et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science: 2006; 311 5757 83 87
100. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest: 2012; 122 3 787 795
101. Herold S., Mayer K., Lohmeyer J. Acute lung injury: how macrophages orchestrate resolution of inflammation and tissue repair. Front Immunol: 2011; 2 65
102. Högner K., Wolff T., Pleschka S., et al. Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog: 2013; 9 2 e1003188
103. Herold S., Steinmueller M., von Wulffen W., et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med: 2008; 205 13 3065 3077
104. Rodrigue-Gervais I. G., Labbé K., Dagenais M., et al. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. Cell Host Microbe: 2014; 15 1 23 35
105. Davidson S., Crotta S., McCabe T. M., Wack A. Pathogenic potential of interferon αβ in acute influenza infection. Nat Commun: 2014; 5 3864
106. Peteranderl C., Morales-Nebreda L., Selvakumar B., et al. Macrophage-epithelial paracrine crosstalk inhibits lung edema clearance during influenza infection. J Clin Invest: 2016; 126 4 1566 1580
107. Unkel B., Hoegner K., Clausen B. E., et al. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J Clin Invest: 2012; 122 10 3652 3664
108. Ichinohe T., Pang I. K., Kumamoto Y., et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A: 2011; 108 13 5354 5359
109. GeurtsvanKessel C. H., Willart M. A., van Rijt L. S., et al. Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J Exp Med: 2008; 205 7 1621 1634
110. Soloff A. C., Bissel S. J., Junecko B. F., et al. Massive mobilization of dendritic cells during influenza A virus subtype H5N1 infection of nonhuman primates. J Infect Dis: 2014; 209 12 2012 2016
111. Fernandez M., Miller E., Krammer F., Greenbaum B., Bhardwaj N. Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells. J Leukoc Biol: 2016; 99 5 723 734
112. Ichinohe T., Lee H. K., Ogura Y., Flavell R., Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med: 2009; 206 1 79 87
113. Hufford M. M., Kim T. S., Sun J., Braciale T. J. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J Exp Med: 2011; 208 1 167 180
114. Hufford M. M., Richardson G., Zhou H., et al. Influenza-infected neutrophils within the infected lungs act as antigen presenting cells for anti-viral CD8(+) T cells. PLoS ONE: 2012; 7 10 e46581
115. McGill J., Van Rooijen N., Legge K. L. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J Exp Med: 2008; 205 7 1635 1646
116. Kim T. S., Sun J., Braciale T. J. T cell responses during influenza infection: getting and keeping control. Trends Immunol: 2011; 32 5 225 231
117. Teijaro J. R., Walsh K. B., Cahalan S., et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell: 2011; 146 6 980 991
118. Zeng H., Pappas C., Belser J. A., et al. Human pulmonary microvascular endothelial cells support productive replication of highly pathogenic avian influenza viruses: possible involvement in the pathogenesis of human H5N1 virus infection. J Virol: 2012; 86 2 667 678
119. Ocaña-Macchi M., Bel M., Guzylack-Piriou L., et al. Hemagglutinin-dependent tropism of H5N1 avian influenza virus for human endothelial cells. J Virol: 2009; 83 24 12947 12955
120. Ishiguro N., Takada A., Yoshioka M., et al. Induction of interferon-inducible protein-10 and monokine induced by interferon-gamma from human endothelial cells infected with Influenza A virus. Arch Virol: 2004; 149 1 17 34
121. Visseren F. L., Verkerk M. S., Bouter K. P., Diepersloot R. J., Erkelens D. W. Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus. J Lab Clin Med: 1999; 134 6 623 630
122. Huang F., Guo J., Zou Z., et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun: 2014; 5 3595
123. Zou Z., Yan Y., Shu Y., et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun: 2014; 5 3594
124. Teijaro J. R., Walsh K. B., Rice S., Rosen H., Oldstone M. B. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A: 2014; 111 10 3799 3804
125. Smith N. M., Bresee J. S., Shay D. K., Uyeki T. M., Cox N. J., Strikas R. A.; Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep: 2006; 55 (RR-10) 1 42
126. WHO WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) and other Influenza Viruses. 2009. Available at: www.who.int/csr/resources/publications/swineflu/h1n1-guidelines-pharmaceutical-mngt.pdf
127. People at High Risk of Developing Flu-Related Complications. 2015. Available at: http://www.cdc.gov/flu/about/disease/high-risk.htm. Accessed August 19, 2015
128. Louie J. K., Acosta M., Samuel M. C., et al. California Pandemic (H1N1) Working Group. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis: 2011; 52 3 301 312
129. Louie J. K., Acosta M., Winter K., et al. California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA: 2009; 302 17 1896 1902
130. Van Kerkhove M. D., Vandemaele K. A., Shinde V., et al. WHO Working Group for Risk Factors for Severe H1N1pdm Infection. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med: 2011; 8 7 e1001053
131. Shinya K., Ebina M., Yamada S., Ono M., Kasai N., Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature: 2006; 440 7083 435 436
132. van Riel D., den Bakker M. A., Leijten L. M., et al. Seasonal and pandemic human influenza viruses attach better to human upper respiratory tract epithelium than avian influenza viruses. Am J Pathol: 2010; 176 4 1614 1618
133. Mauad T., Hajjar L. A., Callegari G. D., et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med: 2010; 181 1 72 79
134. Rello J., Pop-Vicas A. Clinical review: primary influenza viral pneumonia. Crit Care: 2009; 13 6 235
135. Rynda-Apple A., Robinson K. M., Alcorn J. F. Influenza and bacterial superinfection: illuminating the immunologic mechanisms of disease. Infect Immun: 2015; 83 10 3764 3770
136. Blyth C. C., Webb S. A., Kok J., et al. ANZIC Influenza Investigators; COSI Microbiological Investigators. The impact of bacterial and viral co-infection in severe influenza. Influenza Other Respi Viruses: 2013; 7 2 168 176
137. Goka E., Vallely P., Mutton K., Klapper P. Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality. Influenza Other Respi Viruses: 2013; 7 6 1079 1087
138. Stefanska I., Romanowska M., Donevski S., Gawryluk D., Brydak L. B. Co-infections with influenza and other respiratory viruses. Adv Exp Med Biol: 2013; 756 291 301
139. Dobson J., Whitley R. J., Pocock S., Monto A. S. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet: 2015; 385 9979 1729 1737
140. Storms A. D., Gubareva L. V., Su S., et al. US Antiviral Resistance Surveillance Working Group. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis: 2012; 18 2 308 311
141. Dunning J., Baillie J. K., Cao B., Hayden F. G.; International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis: 2014; 14 12 1259 1270
142. Louie J. K., Yang S., Acosta M., et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis: 2012; 55 9 1198 1204
143. Perez-Padilla R., de la Rosa-Zamboni D., Ponce de Leon S., et al. INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med: 2009; 361 7 680 689
144. Napolitano L. M., Park P. K., Raghavendran K., Bartlett R. H. Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure. Crit Care Med: 2010; 38 (4, Suppl): e74 e90
145. Estenssoro E., Ríos F. G., Apezteguía C., et al. Registry of the Argentinian Society of Intensive Care SATI. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med: 2010; 182 1 41 48
146. Ventetuolo C. E., Muratore C. S. Extracorporeal life support in critically ill adults. Am J Respir Crit Care Med: 2014; 190 5 497 508
147. Kim S. H., Hong S. B., Yun S. C., et al. Korean Society of Critical Care Medicine H1N1 Collaborative. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med: 2011; 183 9 1207 1214
148. Hui D. S., Lee N., Chan P. K. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest: 2010; 137 4 916 925
149. Jain S., Benoit S. R., Skarbinski J., Bramley A. M., Finelli L.; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Influenza-associated pneumonia among hospitalized patients with 2009 pandemic influenza A (H1N1) virus-United States, 2009. Clin Infect Dis: 2012; 54 9 1221 1229
150. Morens D. M., Taubenberger J. K., Harvey H. A., Memoli M. J. The 1918 influenza pandemic: lessons for 2009 and the future. Crit Care Med: 2010; 38 (4, Suppl): e10 e20
151. Cortes Garcia M., Sierra Moros M. J., Santa-Olalla Peralta P., Hernandez-Barrera V., Jimenez-Garcia R., Pachon I. Clinical characteristics and outcomes of diabetic patients who were hospitalised with 2009 pandemic influenza A H1N1 infection. J Infect: 2012; 64 2 218 224
152. Rodríguez-Rieiro C., Carrasco-Garrido P., Hernández-Barrera V., et al. Pandemic influenza hospitalization in Spain (2009): incidence, in-hospital mortality, comorbidities and costs. Hum Vaccin Immunother: 2012; 8 4 443 447
153. CDC People at High Risk of Developing Flu-Related Complications; 2015. Available at: http://www.cdc.gov/flu/about/disease/high-risk.htm. Accessed July 17, 2015
154. Memoli M. J., Athota R., Reed S., et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis: 2014; 58 2 214 224
155. Camargo L. F., de Sandes-Freitas T. V., Silva C. D., et al. Morbimortality of pandemic influenza A H1N1 infection in kidney transplant recipients requiring hospitalization: a comparative analysis with nonimmunocompromised patients. Transplantation: 2012; 93 1 69 72
156. ANZIC Influenza Investigators and Australasian Maternity Outcomes Surveillance System Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study. BMJ: 2010; 340 c1279
157. Mosby L. G., Rasmussen S. A., Jamieson D. J. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol: 2011; 205 1 10 18
158. World Health Organization Pregnancy and Pandemic Influenza A (H1N1) 2009: Information for Programme Managers and Clinicians; 2010. Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1-guidance-pregnancy.pdf?ua=1. Accessed July 20, 2015
159. Centers for Disease Control and Prevention (CDC) Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)-United States, April 2009-August 2010. MMWR Morb Mortal Wkly Rep: 2011; 60 35 1193 1196
160. Forbes R. L., Wark P. A., Murphy V. E., Gibson P. G. Pregnant women have attenuated innate interferon responses to 2009 pandemic influenza A virus subtype H1N1. J Infect Dis: 2012; 206 5 646 653
161. Acs N., Bánhidy F., Puhó E., Czeizel A. E. Maternal influenza during pregnancy and risk of congenital abnormalities in offspring. Birth Defects Res A Clin Mol Teratol: 2005; 73 12 989 996
162. Seasonal influenza vaccination in Europe-Vaccination recommendations and coverage rates, 2012-2013. Available at: http://ecdc.europa.eu/en/healthtopics/seasonal-influenza/vaccines/Pages/vaccines.aspx. Accessed October 16, 2015
163. Albright F. S., Orlando P., Pavia A. T., Jackson G. G., Cannon Albright L. A. Evidence for a heritable predisposition to death due to influenza. J Infect Dis: 2008; 197 1 18 24
164. Everitt A. R., Clare S., Pertel T., et al. GenISIS Investigators; MOSAIC Investigators. IFITM3 restricts the morbidity and mortality associated with influenza. Nature: 2012; 484 7395 519 523
165. Wang Z., Zhang A., Wan Y., et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A: 2014; 111 2 769 774
166. Mills T. C., Rautanen A., Elliott K. S., et al. IFITM3 and susceptibility to respiratory viral infections in the community. J Infect Dis: 2014; 209 7 1028 1031
167. Williams D. E., Wu W. L., Grotefend C. R., et al. IFITM3 polymorphism rs12252-C restricts influenza A viruses. PLoS ONE: 2014; 9 10 e110096
168. Ciancanelli M. J., Huang S. X., Luthra P., et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science: 2015; 348 6233 448 453
169. Liu Y., Li S., Zhang G., et al. Genetic variants in IL1A and IL1B contribute to the susceptibility to 2009 pandemic H1N1 influenza A virus. BMC Immunol: 2013; 14 37
170. Cheng Z., Zhou J., To K. K., et al. Identification of TMPRSS2 as a Susceptibility Gene for Severe 2009 Pandemic A(H1N1) Influenza and A(H7N9) Influenza. J Infect Dis: 2015; 212 8 1214 1221
171. Chen Y., Zhou J., Cheng Z., et al. Functional variants regulating LGALS1 (Galectin 1) expression affect human susceptibility to influenza A(H7N9). Sci Rep: 2015; 5 8517
172. Reed C., Kim I. K., Singleton J. A., et al. Centers for Disease Control and Prevention (CDC). Estimated influenza illnesses and hospitalizations averted by vaccination-United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep: 2014; 63 49 1151 1154
173. Grohskopf L. A., Sokolow L. Z., Olsen S. J., Bresee J. S., Broder K. R., Karron R. A. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep: 2015; 64 30 818 825
174. Lukashevich I. S., Shirwan H., eds. Novel Technologies for Vaccine Development. Vienna Springer: 2014
175. Clements M. L., Murphy B. R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol: 1986; 23 1 66 72
176. Nunes-Alves C. Viral infection: stemming influenza viruses. Nat Rev Microbiol: 2015; 13 10 599
177. Impagliazzo A., Milder F., Kuipers H., et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science: 2015; 349 6254 1301 1306
178. Dempsey L. A. Universal influenza vaccine. Nat Immunol: 2015; 16 1013
179. Maassab H. F. Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol: 1969; 102 3 728 732
180. Beyer W. E., Palache A. M., de Jong J. C., Osterhaus A. D. Cold-adapted live influenza vaccine verss inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine: 2002; 20 9-10 1340 1353
181. Fleury D., Barrère B., Bizebard T., Daniels R. S., Skehel J. J., Knossow M. A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site. Nat Struct Biol: 1999; 6 6 530 534
182. Wei G., Meng W., Guo H., et al. Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS ONE: 2011; 6 12 e28309
183. Smee D. F., Bailey K. W., Wong M. H., et al. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res: 2008; 80 3 266 271
184. Furuta Y., Takahashi K., Shiraki K., et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res: 2009; 82 3 95 102
185. Furuta Y., Takahashi K., Fukuda Y., et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother: 2002; 46 4 977 981
186. Sidwell R. W., Smee D. F. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs: 2002; 11 6 859 869
187. Weight A. K., Haldar J., Alvarez de Cienfuegos L., et al. Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus. J Pharm Sci: 2011; 100 3 831 835
188. Mitrasinovic P. M. Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets: 2010; 11 3 315 326
189. Lin L., Liu Q., Berube N., Detmer S., Zhou Y. 5′-Triphosphate-short interfering RNA: potent inhibition of influenza A virus infection by gene silencing and RIG-I activation. J Virol: 2012; 86 19 10359 10369
190. Tompkins S. M., Lo C. Y., Tumpey T. M., Epstein S. L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A: 2004; 101 23 8682 8686
191. Loregian A., Mercorelli B., Nannetti G., Compagnin C., Palù G. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci: 2014; 71 19 3659 3683
192. Malakhov M. P., Aschenbrenner L. M., Smee D. F., et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother: 2006; 50 4 1470 1479
193. Triana-Baltzer G. B., Sanders R. L., Hedlund M., et al. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother: 2011; 66 1 15 28
194. Triana-Baltzer G. B., Gubareva L. V., Klimov A. I., et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS ONE: 2009; 4 11 e7838
195. Kido H., Okumura Y., Yamada H., Le T. Q., Yano M. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr Pharm Des: 2007; 13 4 405 414
196. Ludwig S., Zell R., Schwemmle M., Herold S. Influenza, a One Health paradigm-novel therapeutic strategies to fight a zoonotic pathogen with pandemic potential. Int J Med Microbiol: 2014; 304 7 894 901
197. Register E. CT. Available at: https://wwwclinicaltrialsregistereu/ctr-search/trial/2012-004072-19/DE
198. Wang X., Hinson E. R., Cresswell P. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe: 2007; 2 2 96 105
199. Morita M., Kuba K., Ichikawa A., et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell: 2013; 153 1 112 125
200. Aver'ianov A. V., Babkin A. P., Bart BIa., et al. Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial [in Russian]. Antibiot Khimioter: 2012; 57 7-8 23 30
201. Sever-Chroneos Z., Murthy A., Davis J., et al. GM-CSF modulates pulmonary resistance to influenza A infection. Antiviral Res: 2011; 92 2 319 328
202. Cakarova L., Marsh L. M., Wilhelm J., et al. Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor: impact on alveolar epithelial repair. Am J Respir Crit Care Med: 2009; 180 6 521 532
203. Huang F. F., Barnes P. F., Feng Y., et al. GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med: 2011; 184 2 259 268
204. Herold S., Hoegner K., Vadász I., et al. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med: 2014; 189 5 609 611
205. Ho M. S., Mei S. H., Stewart D. J. The immunomodulatory and therapeutic effects of mesenchymal stromal cells for acute lung injury and sepsis. J Cell Physiol: 2015; 230 11 2606 2617
206. Lalu M. M., Moher D., Marshall J., et al. Canadian Critical Care Translational Biology Group. Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol. Syst Rev: 2014; 3 48
207. Wilson J. G., Liu K. D., Zhuo H., et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med: 2015; 3 1 24 32
208. Weiss D. J. Cell therapies for ARDS: a promising start. Lancet Respir Med: 2015; 3 1 2 3
209. Leeman K. T., Fillmore C. M., Kim C. F. Lung stem and progenitor cells in tissue homeostasis and disease. Curr Top Dev Biol: 2014; 107 207 233
210. Vaughan A. E., Brumwell A. N., Xi Y., et al. Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury. Nature: 2015; 517 7536 621 625
211. Quantius J., Schmoldt C., Vazquez-Armendariz I., et al. Influenza Virus infects epithelial stem/progenitor cells of the distal lung: impact on Fgfr2b-driven epithelial repair. PLOS Pathog: 2016;; in press